Molecular and proliferation markers (Ki67, thymidylate synthase, p53, KRAS, and BRAF) may contribute to the prediction of outcomes post-ablation, offering a valuable stratification tool for tumor-tailored therapeutic approach [11]. This evidence concerns the gene KRAS and neoplasm.